NCT07021937Not yet recruitingPhase 3
Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity
Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 3 Jun 2025
- Start date
- 15 Jun 2026
- Primary completion date
- 30 Apr 2031
- Lead sponsor
- University of Colorado, Denver
- Diseases
- Obesity
- NCT number
- NCT07021937
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 120
- From 15 Jun 2026 to the primary completion date, 30 Apr 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- treated with glucagon-like peptide-1 (GLP-1) agonists (e.g., exenatide, liraglutide, semaglutide, tirzepatide) for weight management in the prior 3 months
- currently taking anti-psychotic medications (anti-depressants accepted)
- any contraindication to receiving a MRI (e.g., orthodontal braces)
Other illness
- diagnosis of type 2 diabetes
- neurological disorder (e.g., Parkinson's disease) or history of stroke
- psychological/behavioral dysfunction (e.g., autism spectrum disorder) or physical impairment that would interfere with study procedures, as determined by study physician
Other
- current or lifetime anorexia nervosa or current bulimia nervosa
- head injury resulting in loss of consciousness \>30min
- if female, desiring to become pregnant, or currently pregnant or breastfeeding
Who the study is looking for
- English-speaking
- male or female (sex assigned at birth)
- 12-18 y/o with obesity (BMI\>120% of the 95th %ile)
- 30-45 y/o with obesity (BMI\>35 kg/m2)
Age in the registry: 12 years to 45 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Colorado Anschutz Medical Campus Coordinator of this site? Confirm its status | Aurora | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.